- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06346704
Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis (NHS-MS-EGYPT)
March 29, 2024 updated by: SYSNAV
Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis (NHS-MS-EGYPT)
The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis.
The Syde® collected data will be compared to on-site conventional clinical endpoints for MS pathology (EDSS, FSS and T25FWT).
Subjects with multiple sclerosis will be assessed every 6 months for 2 years.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ferial Toumi
- Phone Number: +33 2 78 00 10 98
- Email: ferial.toumi@sysnav.fr
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Subjects followed for multiple sclerosis care at the investigational site.
Description
Inclusion Criteria:
- Male or female subject aged from 18 to 65 years old.
- Signed informed consent and ability to comply with study and follow-up.
- Diagnosed with MS base on 2017 McDonald criterion
- EDSS ≤ 5.5
- No clinical or radiological relapse within the last 3 months
- For patient under treatment, the molecule and its dose should be stable about 2 months before inclusion
- Subject willing and able to comply to all study procedures including the Syde® related ones
Exclusion Criteria:
- Patient with a cognitive or communicational disorder disturbing the understanding of the tasks or data collection
- Previous or current disorder with an impact on current ambulation or motor function
- Patient who have had surgery or traumatic injury in upper or lower limb within the last 6 months before the inclusion or patients who have had major surgery or trauma within the last 6 months before the inclusion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Longitudinal change of 95th centile of stride velocity
Time Frame: 2 years
|
change between baseline and Month 6, Month 12, Month 18 and Month 24
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation of the Syde® variables with the clinical assessments EDSS, FSS and T25FWT
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ahmed Elnemr, MD, Air Force Specialized Hospital Cairo
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 25, 2024
Primary Completion (Estimated)
November 30, 2026
Study Completion (Estimated)
November 30, 2026
Study Registration Dates
First Submitted
March 29, 2024
First Submitted That Met QC Criteria
March 29, 2024
First Posted (Actual)
April 4, 2024
Study Record Updates
Last Update Posted (Actual)
April 4, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR5030-66
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Digital HealthTechnology
-
South London and Maudsley NHS Foundation TrustUnknownFirst Episode PsychosisUnited Kingdom
-
Chang Gung Memorial HospitalCompletedStroke | Cerebrovascular Disorders | Central Nervous System DiseasesTaiwan
-
Swing Therapeutics, Inc.CompletedFibromyalgiaUnited States
-
Swing Therapeutics, Inc.CompletedFibromyalgiaUnited States
-
Stanford UniversitySleep Research Society FoundationRecruitingInsomniaUnited States
-
University of RochesterCompleted
-
Scripps Whittier Diabetes InstituteSan Diego State University; University of California, San DiegoCompletedDiabetes Mellitus, Type 2United States
-
Concordia Dent SrlCarol Davila University of Medicine and Pharmacy; MINECCompletedPartially Edentulous Maxilla | Partially Edentulous MandibleRomania
-
Lumos Labs, Inc.RecruitingCognition | Brain Health | Brain Function | Brain StructureUnited States
-
University of California, San FranciscoStanford UniversityRecruiting